VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q61022829  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241221010730.0
008     241221nneanz||abbn n and d
035 ‎‡a  (WKP)Q61022829‏
024 ‎‡a  0000-0002-3553-0963‏ ‎‡2  orcid‏
024 ‎‡a  6603445115‏ ‎‡2  scopus‏
035 ‎‡a  (OCoLC)Q61022829‏
100 0 ‎‡a  Vicente Bertomeu Martínez‏ ‎‡c  researcher ORCID ID = 0000-0002-3553-0963‏ ‎‡9  en‏
375 ‎‡a  1‏ ‎‡2  iso5218‏
400 0 ‎‡a  Vicente Bertomeu Martínez‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
670 ‎‡a  Author's [8-hydroxy-2'-deoxyguanosine and lipid peroxidation in patients with heart failure]‏
670 ‎‡a  Author's Addition of Antiangina Drugs and Recurrent Cardiovascular Events Associated With Incomplete Revascularization in Acute Coronary Syndrome.‏
670 ‎‡a  Author's Additive value of diabetes and peripheral arterial disease in the risk stratification of patients admitted after an acute coronary syndrome: a subanalysis of the PAMISCA Study‏
670 ‎‡a  Author's Anticoagulation prescription in atrial fibrillation‏
670 ‎‡a  Author's [Antithrombotic treatment in hypertensive patients with chronic atrial fibrillation. CARDIOTENS 99 study]‏
670 ‎‡a  Author's [Are therapeutic LDL goals justified? Controversies between the European and American guidelines].‏
670 ‎‡a  Author's Association of Body Mass Index With Clinical Outcomes in Patients With Atrial Fibrillation: A Report From the FANTASIIA Registry‏
670 ‎‡a  Author's Beneficios del tratamiento con estatinas según los valores plasmáticos del antígeno carbohidrato 125 tras un ingreso por insuficiencia cardiaca aguda‏
670 ‎‡a  Author's Blood pressure control in hypertensive women aged 65 years or older in a primary care setting. MERICAP study‏
670 ‎‡a  Author's Burden of systemic hypertension in patients admitted to cardiology hospitalization units‏
670 ‎‡a  Author's C-peptide as a risk factor of coronary artery disease in the general population.‏
670 ‎‡a  Author's Cardiac incoordination induced by left bundle branch block: its relation with left ventricular systolic function in patients with and without cardiomyopathy‏
670 ‎‡a  Author's Carotid resistive index in treated hypertensive patients: relationship with target organ damage‏
670 ‎‡a  Author's Changes in Acute Coronary Syndrome Treatment and Prognosis After Implementation of the Infarction Code in a Hospital With a Cardiac Catheterization Unit.‏
670 ‎‡a  Author's Characteristics and outcome of acute myocardial infarction in young patients. The PRIAMHO II study‏
670 ‎‡a  Author's Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study‏
670 ‎‡a  Author's Circulating biomarkers of collagen metabolism in arterial hypertension: relevance of target organ damage.‏
670 ‎‡a  Author's Clinical course of acute myocardial infarction in the hypertensive patient in Eastern Spain: the PRIMVAC registry‏
670 ‎‡a  Author's [Clinical features and hospital complications of patients with acute coronary syndromes according to smoking habits]‏
670 ‎‡a  Author's Clinical profile and prognosis of patients with low-density lipoprotein cholesterol <70mg/dL and acute coronary syndrome.‏
670 ‎‡a  Author's Comparison of Long-Term Mortality for Cardiac Diseases in Patients With Versus Without Diabetes Mellitus‏
670 ‎‡a  Author's Conocimiento y aplicación de las guías de práctica clínica sobre riesgo cardiovascular en las consultas generales y especializadas‏
670 ‎‡a  Author's Control of cardiovascular risk factors in revascularized patients with diabetes: a subanalysis of the ICP-Bypass study‏
670 ‎‡a  Author's Degree of Anticoagulation Control in Patients With Atrial Fibrillation in Spain: Need to Minimize Biases and Contextualize Results. Response by Anguita Sánchez et al‏
670 ‎‡a  Author's [Diagnostic accuracy of NT-proBNP compared with electrocardiography in detecting left ventricular hypertrophy of hypertensive origin]‏
670 ‎‡a  Author's Differences in medical treatment of chronic coronary heart disease patients according to medical specialities.‏
670 ‎‡a  Author's Differences in the Characteristics and Management of Patients With Atrial Fibrillation Followed-up by Cardiologists and Other Specialists‏
670 ‎‡a  Author's Differential Effect of β-Blockers for Heart Rate Control in Coronary Artery Disease‏
670 ‎‡a  Author's Differential prognostic effect of systolic blood pressure on mortality according to left-ventricular function in patients with acute heart failure‏
670 ‎‡a  Author's Diuretic Strategies in Acute Heart Failure and Renal Dysfunction: Conventional vs Carbohydrate Antigen 125-guided Strategy. Clinical Trial Design‏
670 ‎‡a  Author's Do physicians correctly calculate thromboembolic risk scores? A comparison of concordance between manual and computer-based calculation of CHADS2 and CHA2 DS2 -VASc scores‏
670 ‎‡a  Author's [Does the metabolic syndrome need more descriptive studies or more evidence of its implication in secondary prevention?]‏
670 ‎‡a  Author's Echocardiographic evaluation of the evolutionary changes after heart transplantation‏
670 ‎‡a  Author's Effectiveness of a new health care organization model in primary care for chronic cardiovascular disease patients based on a multifactorial intervention: the PROPRESE randomized controlled trial.‏
670 ‎‡a  Author's [Electrocardiographic criteria for left ventricular hypertrophy and cardiovascular risk in hypertensives. VIIDA study]‏
670 ‎‡a  Author's Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents.‏
670 ‎‡a  Author's [Evolution and scientific impact of research grants from the spanish society of cardiology and spanish heart foundation‏
670 ‎‡a  Author's Evolution and scientific impact of research grants from the spanish society of cardiology and spanish heart foundation (2000-2006)‏
670 ‎‡a  Author's [Factors associated with uncontrolled hypertension in patients with and without cardiovascular disease]‏
670 ‎‡a  Author's Heart Failure, Nonvalvular Atrial Fibrillation and Anticoagulation Control With Vitamin K Antagonists‏
670 ‎‡a  Author's High heart rate: more than a risk factor. Lessons from a clinical practice survey‏
670 ‎‡a  Author's [How beta-blockers are used in Spain? Analysis of limitations in their use in internal medicine and cardiology: CARACTER-BETA study]‏
670 ‎‡a  Author's [How to carry out the search of cardiovascular disease in patients with renal insufficiency?]‏
670 ‎‡a  Author's [Hypertension and health policy in Spain]‏
670 ‎‡a  Author's [Immunological alterations and selectin values in hypertensive patients treated according to current criteria]‏
670 ‎‡a  Author's [Impact of blood pressure control on the ankle-brachial index in hypertensive patients]‏
670 ‎‡a  Author's Impact of cardiovascular risk factors and inflammatory status on urinary 8-OHdG in essential hypertension‏
670 ‎‡a  Author's Impact of clinical and subclinical peripheral arterial disease in mid-term prognosis of patients with acute coronary syndrome‏
670 ‎‡a  Author's Impact of glomerular filtration rate on urinary BNP and NT-proBNP levels in heart failure.‏
670 ‎‡a  Author's Impact of new criteria for anticoagulant treatment in atrial fibrillation‏
670 ‎‡a  Author's In-hospital mortality due to acute myocardial infarction. relevance of type of hospital and care provided. RECALCAR study‏
670 ‎‡a  Author's Inflammation and apoptosis in hypertension. Relevance of the extent of target organ damage‏
670 ‎‡a  Author's [Influence of antecedent of hypertension in patients with acute coronary syndrome without ST elevation]‏
670 ‎‡a  Author's [Interleukin-4 and cardiac fibrosis in patients with heart failure]‏
670 ‎‡a  Author's [Introduction]‏
670 ‎‡a  Author's Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?‏
670 ‎‡a  Author's [Last developments on hypertension]‏
670 ‎‡a  Author's Left ventricular cavity area reflects N-terminal pro-brain natriuretic peptide plasma levels in heart failure.‏
670 ‎‡a  Author's Long-term prognosis, readmissions and potential years of life lost in young patients after a hospital admission for heart failure‏
670 ‎‡a  Author's Low levels of high-density lipoproteins cholesterol are independently associated with acute coronary heart disease in patients hospitalized for chest pain.‏
670 ‎‡a  Author's Low lymphocyte count in acute phase of ST-segment elevation myocardial infarction predicts long-term recurrent myocardial infarction.‏
670 ‎‡a  Author's [Magnitude and characteristics of residual lipid risk in patients with a history of coronary revascularization: the ICP-bypass study]‏
670 ‎‡a  Author's Metformin and risk of long-term mortality following an admission for acute heart failure‏
670 ‎‡a  Author's Multimarker risk strategy for predicting 1-month and 1-year major events in non-ST-elevation acute coronary syndromes.‏
670 ‎‡a  Author's Obese and nonobese patients with essential hypertension show similar N-terminal proBNP plasma levels‏
670 ‎‡a  Author's Obese subjects with heart failure have lower N-terminal pro-brain natriuretic peptide plasma levels irrespective of aetiology‏
670 ‎‡a  Author's Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: Results from the CAPS study.‏
670 ‎‡a  Author's Oral anticoagulation in octogenarians with atrial fibrillation.‏
670 ‎‡a  Author's Pathological ankle-brachial index is equivalent of advanced age in acute coronary syndromes‏
670 ‎‡a  Author's Patterns of inpatient care for acute myocardial infarction and 30-day, 3-month and 1-year cardiac diseases readmission rates in Spain.‏
670 ‎‡a  Author's Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: A report from the FANTASIIA registry‏
670 ‎‡a  Author's Plasma concentration of big endothelin-1 and its relation with plasma NT-proBNP and ventricular function in heart failure patients‏
670 ‎‡a  Author's Prevalence and prognostic influence of peripheral arterial disease in patients >or=40 years old admitted into hospital following an acute coronary event.‏
670 ‎‡a  Author's Prevalencia de fibrilación auricular y uso de fármacos antitrombóticos en el paciente hipertenso ≥ 65 años. El registro FAPRES.‏
670 ‎‡a  Author's Prognostic usefulness of white blood cell count on admission and one-year outcome in patients with non-ST-segment elevation acute chest pain‏
670 ‎‡a  Author's Prognostic value of low ankle-brachial index in patients with hypertension and acute coronary syndromes‏
670 ‎‡a  Author's [Prognostic value of white blood cell count in acute myocardial infarction: long-term mortality]‏
670 ‎‡a  Author's Quality Improvement Strategy of the Spanish Society of Cardiology: The RECALCAR Registry.‏
670 ‎‡a  Author's Quality of Anticoagulation With Vitamin K Antagonists.‏
670 ‎‡a  Author's Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry.‏
670 ‎‡a  Author's Quality of Vitamin K Antagonist Anticoagulation in Spain: Prevalence of Poor Control and Associated Factors.‏
670 ‎‡a  Author's Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIIA Registry.‏
670 ‎‡a  Author's [Relationship between myocardial modelling and diastolic function in patients with essential hypertension]‏
670 ‎‡a  Author's Relationship of adverse events to quality of anticoagulation control in atrial fibrillation patients with diabetes: Real-world data from the FANTASIIA registry‏
670 ‎‡a  Author's RNA-sequencing analysis reveals new alterations in cardiomyocyte cytoskeletal genes in patients with heart failure‏
670 ‎‡a  Author's [Self-measurement of blood pressure. Consensus Paper Spain 2007]‏
670 ‎‡a  Author's Short-term metabolic changes achieved by weight loss in hypertensive patients.‏
670 ‎‡a  Author's Soluble TNF-α and interleukin-6 receptors in the urine of heart failure patients. Their clinical value and relationship with plasma levels‏
670 ‎‡a  Author's [Strategies for effective control of arterial hypertension in Spain. Consensus document]‏
670 ‎‡a  Author's Structural Heart Disease in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Prevalence and Clinical Profile in a Spanish Sample‏
670 ‎‡a  Author's [The PROPRESE trial: results of a new health care organizational model in primary care for patients with chronic coronary heart disease based on a multifactorial intervention]‏
670 ‎‡a  Author's The RECALCAR Project. Healthcare in the Cardiology Units of the Spanish National Health System, 2011 to 2014.‏
670 ‎‡a  Author's Tratamiento de la hiperglucemia en el hospital‏
670 ‎‡a  Author's [Treatment of acute myocardial infarction by primary angioplasty on-site compared with treatment following interhospital transfer: short- and long-time clinical outcomes]‏
670 ‎‡a  Author's Trends in clinical profile and medical treatments of atrial fibrillation patients over the last 10 years.‏
670 ‎‡a  Author's Trends in Risk Factors and Treatments in Patients With Stable Ischemic Heart Disease Seen at Cardiology Clinics Between 2006 and 2014.‏
670 ‎‡a  Author's Update in cardiology: vascular risk and cardiac rehabilitation‏
670 ‎‡a  Author's Urinary B-type natriuretic peptide levels in the diagnosis and prognosis of heart failure‏
670 ‎‡a  Author's Usefulness of a comprehensive cardiovascular magnetic resonance imaging assessment for predicting recovery of left ventricular wall motion in the setting of myocardial stunning.‏
670 ‎‡a  Author's Usefulness of concomitant myoglobin and troponin elevation as a biochemical marker of mortality in non-ST-segment elevation acute coronary syndromes‏
670 ‎‡a  Author's Usefulness of NT-proBNP level for diagnosing left ventricular hypertrophy in hypertensive patients. A cardiac magnetic resonance study.‏
670 ‎‡a  Author's Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists‏
670 ‎‡a  Author's Valsalva sinus pseudoaneurysm causes acute myocardial infarction and stroke simultaneously‏
670 ‎‡a  Author's Variability of NT-proBNP and its relationship with inflammatory status in patients with stable essential hypertension: a 2-year follow-up study.‏
670 ‎‡a  Author's Ventricular hypertrophy increases NT-proBNP in subjects with and without hypertension‏
670 ‎‡a  Author's [What measure of carotid wall thickening is the best atherosclerotic loading score in the hypertensive patient: maximum or mean value?]‏
670 ‎‡a  Author's ভূমিকা‏
909 ‎‡a  (scopus) 6603445115‏ ‎‡9  1‏
909 ‎‡a  (orcid) 0000000235530963‏ ‎‡9  1‏
912 ‎‡a  introduction‏ ‎‡A  [Introduction]‏ ‎‡9  1‏
912 ‎‡a  ভমক‏ ‎‡A  ভূমিকা‏ ‎‡9  1‏
919 ‎‡a  rnasequencinganalysisrevealsnewalterationsincardiomyocytecytoskeletalgenesinpatientswithheartfailure‏ ‎‡A  RNA-sequencing analysis reveals new alterations in cardiomyocyte cytoskeletal genes in patients with heart failure‏ ‎‡9  1‏
919 ‎‡a  qualityoforalanticoagulationwithvitaminkantagonistsinrealworldpatientswithatrialfibrillationareportfromtheprospectivemulticentrefantasiiaregistry‏ ‎‡A  Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry.‏ ‎‡9  1‏
919 ‎‡a  qualityofanticoagulationwithvitaminkantagonists‏ ‎‡A  Quality of Anticoagulation With Vitamin K Antagonists.‏ ‎‡9  1‏
919 ‎‡a  qualityimprovementstrategyofthespanishsocietyofcardiologytherecalcarregistry‏ ‎‡A  Quality Improvement Strategy of the Spanish Society of Cardiology: The RECALCAR Registry.‏ ‎‡9  1‏
919 ‎‡a  prognosticvalueofwhitebloodcellcountinacutemyocardialinfarctionlongtermmortality‏ ‎‡A  [Prognostic value of white blood cell count in acute myocardial infarction: long-term mortality]‏ ‎‡9  1‏
919 ‎‡a  prognosticvalueoflowanklebrachialindexinpatientswithhypertensionandacutecoronarysyndromes‏ ‎‡A  Prognostic value of low ankle-brachial index in patients with hypertension and acute coronary syndromes‏ ‎‡9  1‏
919 ‎‡a  prognosticusefulnessofwhitebloodcellcountonadmissionand1yearoutcomeinpatientswithnonstsegmentelevationacutechestpain‏ ‎‡A  Prognostic usefulness of white blood cell count on admission and one-year outcome in patients with non-ST-segment elevation acute chest pain‏ ‎‡9  1‏
919 ‎‡a  prevalenciadefibrilacionauricularyusodefarmacosantitromboticosenelpacientehipertenso65anoselregistrofapres‏ ‎‡A  Prevalencia de fibrilación auricular y uso de fármacos antitrombóticos en el paciente hipertenso ≥ 65 años. El registro FAPRES.‏ ‎‡9  1‏
919 ‎‡a  prevalenceandprognosticinfluenceofperipheralarterialdiseaseinpatientsor40yearsoldadmittedintohospitalfollowinganacutecoronaryevent‏ ‎‡A  Prevalence and prognostic influence of peripheral arterial disease in patients >or=40 years old admitted into hospital following an acute coronary event.‏ ‎‡9  1‏
919 ‎‡a  plasmaconcentrationofbigendothelin1anditsrelationwithplasmantprobnpandventricularfunctioninheartfailurepatients‏ ‎‡A  Plasma concentration of big endothelin-1 and its relation with plasma NT-proBNP and ventricular function in heart failure patients‏ ‎‡9  1‏
919 ‎‡a  peripheralarterydiseaseandclinicaloutcomesinpatientswithatrialfibrillationareportfromthefantasiiaregistry‏ ‎‡A  Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: A report from the FANTASIIA registry‏ ‎‡9  1‏
919 ‎‡a  patternsofinpatientcareforacutemyocardialinfarctionand30day3monthand1yearcardiacdiseasesreadmissionratesinspain‏ ‎‡A  Patterns of inpatient care for acute myocardial infarction and 30-day, 3-month and 1-year cardiac diseases readmission rates in Spain.‏ ‎‡9  1‏
919 ‎‡a  pathologicalanklebrachialindexisequivalentofadvancedageinacutecoronarysyndromes‏ ‎‡A  Pathological ankle-brachial index is equivalent of advanced age in acute coronary syndromes‏ ‎‡9  1‏
919 ‎‡a  oralanticoagulationinoctogenarianswithatrialfibrillation‏ ‎‡A  Oral anticoagulation in octogenarians with atrial fibrillation.‏ ‎‡9  1‏
919 ‎‡a  optimalpharmacologicaltreatmentandadherencetomedicationinsecondarypreventionofcardiovasculareventsinspainresultsfromthecapsstudy‏ ‎‡A  Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: Results from the CAPS study.‏ ‎‡9  1‏
919 ‎‡a  obesesubjectswithheartfailurehavelowernterminalprobrainnatriureticpeptideplasmalevelsirrespectiveofaetiology‏ ‎‡A  Obese subjects with heart failure have lower N-terminal pro-brain natriuretic peptide plasma levels irrespective of aetiology‏ ‎‡9  1‏
919 ‎‡a  obeseandnonobesepatientswithessentialhypertensionshowsimilarnterminalprobnpplasmalevels‏ ‎‡A  Obese and nonobese patients with essential hypertension show similar N-terminal proBNP plasma levels‏ ‎‡9  1‏
919 ‎‡a  multimarkerriskstrategyforpredicting1monthand1yearmajoreventsinnonstelevationacutecoronarysyndromes‏ ‎‡A  Multimarker risk strategy for predicting 1-month and 1-year major events in non-ST-elevation acute coronary syndromes.‏ ‎‡9  1‏
919 ‎‡a  metforminandriskoflongtermmortalityfollowinganadmissionforacuteheartfailure‏ ‎‡A  Metformin and risk of long-term mortality following an admission for acute heart failure‏ ‎‡9  1‏
919 ‎‡a  magnitudeandcharacteristicsofresiduallipidriskinpatientswithahistoryofcoronaryrevascularizationtheicpbypassstudy‏ ‎‡A  [Magnitude and characteristics of residual lipid risk in patients with a history of coronary revascularization: the ICP-bypass study]‏ ‎‡9  1‏
919 ‎‡a  lowlymphocytecountinacutephaseofstsegmentelevationmyocardialinfarctionpredictslongtermrecurrentmyocardialinfarction‏ ‎‡A  Low lymphocyte count in acute phase of ST-segment elevation myocardial infarction predicts long-term recurrent myocardial infarction.‏ ‎‡9  1‏
919 ‎‡a  lowlevelsofhighdensitylipoproteinscholesterolareindependentlyassociatedwithacutecoronaryheartdiseaseinpatientshospitalizedforchestpain‏ ‎‡A  Low levels of high-density lipoproteins cholesterol are independently associated with acute coronary heart disease in patients hospitalized for chest pain.‏ ‎‡9  1‏
919 ‎‡a  longtermprognosisreadmissionsandpotentialyearsoflifelostinyoungpatientsafterahospitaladmissionforheartfailure‏ ‎‡A  Long-term prognosis, readmissions and potential years of life lost in young patients after a hospital admission for heart failure‏ ‎‡9  1‏
919 ‎‡a  leftventricularcavityareareflectsnterminalprobrainnatriureticpeptideplasmalevelsinheartfailure‏ ‎‡A  Left ventricular cavity area reflects N-terminal pro-brain natriuretic peptide plasma levels in heart failure.‏ ‎‡9  1‏
919 ‎‡a  lastdevelopmentsonhypertension‏ ‎‡A  [Last developments on hypertension]‏ ‎‡9  1‏
919 ‎‡a  istheorbitbleedingriskscoresuperiortothehasbledscoreinanticoagulatedatrialfibrillationpatients‏ ‎‡A  Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?‏ ‎‡9  1‏
919 ‎‡a  interleukin4andcardiacfibrosisinpatientswithheartfailure‏ ‎‡A  [Interleukin-4 and cardiac fibrosis in patients with heart failure]‏ ‎‡9  1‏
919 ‎‡a  influenceofantecedentofhypertensioninpatientswithacutecoronarysyndromewithoutstelevation‏ ‎‡A  [Influence of antecedent of hypertension in patients with acute coronary syndrome without ST elevation]‏ ‎‡9  1‏
919 ‎‡a  inflammationandapoptosisinhypertensionrelevanceoftheextentoftargetorgandamage‏ ‎‡A  Inflammation and apoptosis in hypertension. Relevance of the extent of target organ damage‏ ‎‡9  1‏
919 ‎‡a  inhospitalmortalityduetoacutemyocardialinfarctionrelevanceoftypeofhospitalandcareprovidedrecalcarstudy‏ ‎‡A  In-hospital mortality due to acute myocardial infarction. relevance of type of hospital and care provided. RECALCAR study‏ ‎‡9  1‏
919 ‎‡a  impactofnewcriteriaforanticoagulanttreatmentinatrialfibrillation‏ ‎‡A  Impact of new criteria for anticoagulant treatment in atrial fibrillation‏ ‎‡9  1‏
919 ‎‡a  impactofglomerularfiltrationrateonurinarybnpandntprobnplevelsinheartfailure‏ ‎‡A  Impact of glomerular filtration rate on urinary BNP and NT-proBNP levels in heart failure.‏ ‎‡9  1‏
919 ‎‡a  impactofclinicalandsubclinicalperipheralarterialdiseaseinmidtermprognosisofpatientswithacutecoronarysyndrome‏ ‎‡A  Impact of clinical and subclinical peripheral arterial disease in mid-term prognosis of patients with acute coronary syndrome‏ ‎‡9  1‏
919 ‎‡a  impactofcardiovascularriskfactorsandinflammatorystatusonurinary8ohdginessentialhypertension‏ ‎‡A  Impact of cardiovascular risk factors and inflammatory status on urinary 8-OHdG in essential hypertension‏ ‎‡9  1‏
919 ‎‡a  impactofbloodpressurecontrolontheanklebrachialindexinhypertensivepatients‏ ‎‡A  [Impact of blood pressure control on the ankle-brachial index in hypertensive patients]‏ ‎‡9  1‏
919 ‎‡a  immunologicalalterationsandselectinvaluesinhypertensivepatientstreatedaccordingtocurrentcriteria‏ ‎‡A  [Immunological alterations and selectin values in hypertensive patients treated according to current criteria]‏ ‎‡9  1‏
919 ‎‡a  hypertensionandhealthpolicyinspain‏ ‎‡A  [Hypertension and health policy in Spain]‏ ‎‡9  1‏
919 ‎‡a  howtocarryoutthesearchofcardiovasculardiseaseinpatientswithrenalinsufficiency‏ ‎‡A  [How to carry out the search of cardiovascular disease in patients with renal insufficiency?]‏ ‎‡9  1‏
919 ‎‡a  howbetablockersareusedinspainanalysisoflimitationsintheiruseininternalmedicineandcardiologycaracterbetastudy‏ ‎‡A  [How beta-blockers are used in Spain? Analysis of limitations in their use in internal medicine and cardiology: CARACTER-BETA study]‏ ‎‡9  1‏
919 ‎‡a  highheartratemorethanariskfactorlessonsfromaclinicalpracticesurvey‏ ‎‡A  High heart rate: more than a risk factor. Lessons from a clinical practice survey‏ ‎‡9  1‏
919 ‎‡a  heartfailurenonvalvularatrialfibrillationandanticoagulationcontrolwithvitaminkantagonists‏ ‎‡A  Heart Failure, Nonvalvular Atrial Fibrillation and Anticoagulation Control With Vitamin K Antagonists‏ ‎‡9  1‏
919 ‎‡a  factorsassociatedwithuncontrolledhypertensioninpatientswithandwithoutcardiovasculardisease‏ ‎‡A  [Factors associated with uncontrolled hypertension in patients with and without cardiovascular disease]‏ ‎‡9  1‏
919 ‎‡a  evolutionandscientificimpactofresearchgrantsfromthespanishsocietyofcardiologyandspanishheartfoundation2000‏ ‎‡A  Evolution and scientific impact of research grants from the spanish society of cardiology and spanish heart foundation (2000-2006)‏ ‎‡9  1‏
919 ‎‡a  evolutionandscientificimpactofresearchgrantsfromthespanishsocietyofcardiologyandspanishheartfoundation‏ ‎‡A  [Evolution and scientific impact of research grants from the spanish society of cardiology and spanish heart foundation‏ ‎‡9  1‏
919 ‎‡a  erectiledysfunctioninhighriskhypertensivepatientstreatedwithbetablockadeagents‏ ‎‡A  Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents.‏ ‎‡9  1‏
919 ‎‡a  electrocardiographiccriteriaforleftventricularhypertrophyandcardiovascularriskinhypertensivesviidastudy‏ ‎‡A  [Electrocardiographic criteria for left ventricular hypertrophy and cardiovascular risk in hypertensives. VIIDA study]‏ ‎‡9  1‏
919 ‎‡a  effectivenessofanewhealthcareorganizationmodelinprimarycareforchroniccardiovasculardiseasepatientsbasedonamultifactorialinterventionthepropreserandomizedcontrolledtrial‏ ‎‡A  Effectiveness of a new health care organization model in primary care for chronic cardiovascular disease patients based on a multifactorial intervention: the PROPRESE randomized controlled trial.‏ ‎‡9  1‏
919 ‎‡a  echocardiographicevaluationoftheevolutionarychangesafterhearttransplantation‏ ‎‡A  Echocardiographic evaluation of the evolutionary changes after heart transplantation‏ ‎‡9  1‏
919 ‎‡a  doesthemetabolicsyndromeneedmoredescriptivestudiesormoreevidenceofitsimplicationinsecondaryprevention‏ ‎‡A  [Does the metabolic syndrome need more descriptive studies or more evidence of its implication in secondary prevention?]‏ ‎‡9  1‏
919 ‎‡a  dophysicianscorrectlycalculatethromboembolicriskscoresacomparisonofconcordancebetweenmanualandcomputerbasedcalculationofchads2andcha2ds2vascscores‏ ‎‡A  Do physicians correctly calculate thromboembolic risk scores? A comparison of concordance between manual and computer-based calculation of CHADS2 and CHA2 DS2 -VASc scores‏ ‎‡9  1‏
919 ‎‡a  diureticstrategiesinacuteheartfailureandrenaldysfunctionconventionalvscarbohydrateantigen125guidedstrategyclinicaltrialdesign‏ ‎‡A  Diuretic Strategies in Acute Heart Failure and Renal Dysfunction: Conventional vs Carbohydrate Antigen 125-guided Strategy. Clinical Trial Design‏ ‎‡9  1‏
919 ‎‡a  differentialprognosticeffectofsystolicbloodpressureonmortalityaccordingtoleftventricularfunctioninpatientswithacuteheartfailure‏ ‎‡A  Differential prognostic effect of systolic blood pressure on mortality according to left-ventricular function in patients with acute heart failure‏ ‎‡9  1‏
919 ‎‡a  differentialeffectofβblockersforheartratecontrolincoronaryarterydisease‏ ‎‡A  Differential Effect of β-Blockers for Heart Rate Control in Coronary Artery Disease‏ ‎‡9  1‏
919 ‎‡a  differencesinthecharacteristicsandmanagementofpatientswithatrialfibrillationfollowedupbycardiologistsandotherspecialists‏ ‎‡A  Differences in the Characteristics and Management of Patients With Atrial Fibrillation Followed-up by Cardiologists and Other Specialists‏ ‎‡9  1‏
919 ‎‡a  differencesinmedicaltreatmentofchroniccoronaryheartdiseasepatientsaccordingtomedicalspecialities‏ ‎‡A  Differences in medical treatment of chronic coronary heart disease patients according to medical specialities.‏ ‎‡9  1‏
919 ‎‡a  diagnosticaccuracyofntprobnpcomparedwithelectrocardiographyindetectingleftventricularhypertrophyofhypertensiveorigin‏ ‎‡A  [Diagnostic accuracy of NT-proBNP compared with electrocardiography in detecting left ventricular hypertrophy of hypertensive origin]‏ ‎‡9  1‏
919 ‎‡a  degreeofanticoagulationcontrolinpatientswithatrialfibrillationinspainneedtominimizebiasesandcontextualizeresultsresponsebyanguitasanchezetal‏ ‎‡A  Degree of Anticoagulation Control in Patients With Atrial Fibrillation in Spain: Need to Minimize Biases and Contextualize Results. Response by Anguita Sánchez et al‏ ‎‡9  1‏
919 ‎‡a  controlofcardiovascularriskfactorsinrevascularizedpatientswithdiabetesasubanalysisoftheicpbypassstudy‏ ‎‡A  Control of cardiovascular risk factors in revascularized patients with diabetes: a subanalysis of the ICP-Bypass study‏ ‎‡9  1‏
919 ‎‡a  conocimientoyaplicaciondelasguiasdepracticaclinicasobreriesgocardiovascularenlasconsultasgeneralesyespecializadas‏ ‎‡A  Conocimiento y aplicación de las guías de práctica clínica sobre riesgo cardiovascular en las consultas generales y especializadas‏ ‎‡9  1‏
919 ‎‡a  comparisonoflongtermmortalityforcardiacdiseasesinpatientswithversuswithoutdiabetesmellitus‏ ‎‡A  Comparison of Long-Term Mortality for Cardiac Diseases in Patients With Versus Without Diabetes Mellitus‏ ‎‡9  1‏
919 ‎‡a  clinicalprofileandprognosisofpatientswithlowdensitylipoproteincholesterol70mg550andacutecoronarysyndrome‏ ‎‡A  Clinical profile and prognosis of patients with low-density lipoprotein cholesterol <70mg/dL and acute coronary syndrome.‏ ‎‡9  1‏
919 ‎‡a  clinicalfeaturesandhospitalcomplicationsofpatientswithacutecoronarysyndromesaccordingtosmokinghabits‏ ‎‡A  [Clinical features and hospital complications of patients with acute coronary syndromes according to smoking habits]‏ ‎‡9  1‏
919 ‎‡a  clinicalcourseofacutemyocardialinfarctioninthehypertensivepatientineasternspaintheprimvacregistry‏ ‎‡A  Clinical course of acute myocardial infarction in the hypertensive patient in Eastern Spain: the PRIMVAC registry‏ ‎‡9  1‏
919 ‎‡a  circulatingbiomarkersofcollagenmetabolisminarterialhypertensionrelevanceoftargetorgandamage‏ ‎‡A  Circulating biomarkers of collagen metabolism in arterial hypertension: relevance of target organ damage.‏ ‎‡9  1‏
919 ‎‡a  choiceofneworalanticoagulantagentsversusvitaminkantagonistsinatrialfibrillationfantasiiastudy‏ ‎‡A  Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study‏ ‎‡9  1‏
919 ‎‡a  characteristicsandoutcomeofacutemyocardialinfarctioninyoungpatientsthepriamho2study‏ ‎‡A  Characteristics and outcome of acute myocardial infarction in young patients. The PRIAMHO II study‏ ‎‡9  1‏
919 ‎‡a  changesinacutecoronarysyndrometreatmentandprognosisafterimplementationoftheinfarctioncodeinahospitalwithacardiaccatheterizationunit‏ ‎‡A  Changes in Acute Coronary Syndrome Treatment and Prognosis After Implementation of the Infarction Code in a Hospital With a Cardiac Catheterization Unit.‏ ‎‡9  1‏
919 ‎‡a  carotidresistiveindexintreatedhypertensivepatientsrelationshipwithtargetorgandamage‏ ‎‡A  Carotid resistive index in treated hypertensive patients: relationship with target organ damage‏ ‎‡9  1‏
919 ‎‡a  cardiacincoordinationinducedbyleftbundlebranchblockitsrelationwithleftventricularsystolicfunctioninpatientswithandwithoutcardiomyopathy‏ ‎‡A  Cardiac incoordination induced by left bundle branch block: its relation with left ventricular systolic function in patients with and without cardiomyopathy‏ ‎‡9  1‏
919 ‎‡a  100peptideasariskfactorofcoronaryarterydiseaseinthegeneralpopulation‏ ‎‡A  C-peptide as a risk factor of coronary artery disease in the general population.‏ ‎‡9  1‏
919 ‎‡a  burdenofsystemichypertensioninpatientsadmittedtocardiologyhospitalizationunits‏ ‎‡A  Burden of systemic hypertension in patients admitted to cardiology hospitalization units‏ ‎‡9  1‏
919 ‎‡a  bloodpressurecontrolinhypertensivewomenaged65yearsorolderinaprimarycaresettingmericapstudy‏ ‎‡A  Blood pressure control in hypertensive women aged 65 years or older in a primary care setting. MERICAP study‏ ‎‡9  1‏
919 ‎‡a  beneficiosdeltratamientoconestatinassegunlosvaloresplasmaticosdelantigenocarbohidrato125tras1ingresoporinsuficienciacardiacaaguda‏ ‎‡A  Beneficios del tratamiento con estatinas según los valores plasmáticos del antígeno carbohidrato 125 tras un ingreso por insuficiencia cardiaca aguda‏ ‎‡9  1‏
919 ‎‡a  associationofbodymassindexwithclinicaloutcomesinpatientswithatrialfibrillationareportfromthefantasiiaregistry‏ ‎‡A  Association of Body Mass Index With Clinical Outcomes in Patients With Atrial Fibrillation: A Report From the FANTASIIA Registry‏ ‎‡9  1‏
919 ‎‡a  aretherapeuticldlgoalsjustifiedcontroversiesbetweentheeuropeanandamericanguidelines‏ ‎‡A  [Are therapeutic LDL goals justified? Controversies between the European and American guidelines].‏ ‎‡9  1‏
919 ‎‡a  antithrombotictreatmentinhypertensivepatientswithchronicatrialfibrillationcardiotens99study‏ ‎‡A  [Antithrombotic treatment in hypertensive patients with chronic atrial fibrillation. CARDIOTENS 99 study]‏ ‎‡9  1‏
919 ‎‡a  anticoagulationprescriptioninatrialfibrillation‏ ‎‡A  Anticoagulation prescription in atrial fibrillation‏ ‎‡9  1‏
919 ‎‡a  additivevalueofdiabetesandperipheralarterialdiseaseintheriskstratificationofpatientsadmittedafteranacutecoronarysyndromeasubanalysisofthepamiscastudy‏ ‎‡A  Additive value of diabetes and peripheral arterial disease in the risk stratification of patients admitted after an acute coronary syndrome: a subanalysis of the PAMISCA Study‏ ‎‡9  1‏
919 ‎‡a  additionofantianginadrugsandrecurrentcardiovasculareventsassociatedwithincompleterevascularizationinacutecoronarysyndrome‏ ‎‡A  Addition of Antiangina Drugs and Recurrent Cardiovascular Events Associated With Incomplete Revascularization in Acute Coronary Syndrome.‏ ‎‡9  1‏
919 ‎‡a  8hydroxy2deoxyguanosineandlipidperoxidationinpatientswithheartfailure‏ ‎‡A  [8-hydroxy-2'-deoxyguanosine and lipid peroxidation in patients with heart failure]‏ ‎‡9  1‏
919 ‎‡a  selfmeasurementofbloodpressureconsensuspaperspain‏ ‎‡A  [Self-measurement of blood pressure. Consensus Paper Spain 2007]‏ ‎‡9  1‏
919 ‎‡a  shorttermmetabolicchangesachievedbyweightlossinhypertensivepatients‏ ‎‡A  Short-term metabolic changes achieved by weight loss in hypertensive patients.‏ ‎‡9  1‏
919 ‎‡a  solubletnfαandinterleukin6receptorsintheurineofheartfailurepatientstheirclinicalvalueandrelationshipwithplasmalevels‏ ‎‡A  Soluble TNF-α and interleukin-6 receptors in the urine of heart failure patients. Their clinical value and relationship with plasma levels‏ ‎‡9  1‏
919 ‎‡a  strategiesforeffectivecontrolofarterialhypertensioninspainconsensusdocument‏ ‎‡A  [Strategies for effective control of arterial hypertension in Spain. Consensus document]‏ ‎‡9  1‏
919 ‎‡a  structuralheartdiseaseinanticoagulatedpatientswithnonvalvularatrialfibrillationprevalenceandclinicalprofileinaspanishsample‏ ‎‡A  Structural Heart Disease in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Prevalence and Clinical Profile in a Spanish Sample‏ ‎‡9  1‏
919 ‎‡a  propresetrialresultsofanewhealthcareorganizationalmodelinprimarycareforpatientswithchroniccoronaryheartdiseasebasedonamultifactorialintervention‏ ‎‡A  [The PROPRESE trial: results of a new health care organizational model in primary care for patients with chronic coronary heart disease based on a multifactorial intervention]‏ ‎‡9  1‏
919 ‎‡a  recalcarprojecthealthcareinthecardiologyunitsofthespanishnationalhealthsystem2011to‏ ‎‡A  The RECALCAR Project. Healthcare in the Cardiology Units of the Spanish National Health System, 2011 to 2014.‏ ‎‡9  1‏
919 ‎‡a  tratamientodelahiperglucemiaenelhospital‏ ‎‡A  Tratamiento de la hiperglucemia en el hospital‏ ‎‡9  1‏
919 ‎‡a  treatmentofacutemyocardialinfarctionbyprimaryangioplastyonsitecomparedwithtreatmentfollowinginterhospitaltransfershortandlongtimeclinicaloutcomes‏ ‎‡A  [Treatment of acute myocardial infarction by primary angioplasty on-site compared with treatment following interhospital transfer: short- and long-time clinical outcomes]‏ ‎‡9  1‏
919 ‎‡a  trendsinclinicalprofileandmedicaltreatmentsofatrialfibrillationpatientsoverthelast10years‏ ‎‡A  Trends in clinical profile and medical treatments of atrial fibrillation patients over the last 10 years.‏ ‎‡9  1‏
919 ‎‡a  trendsinriskfactorsandtreatmentsinpatientswithstableischemicheartdiseaseseenatcardiologyclinicsbetween2006and‏ ‎‡A  Trends in Risk Factors and Treatments in Patients With Stable Ischemic Heart Disease Seen at Cardiology Clinics Between 2006 and 2014.‏ ‎‡9  1‏
919 ‎‡a  updateincardiologyvascularriskandcardiacrehabilitation‏ ‎‡A  Update in cardiology: vascular risk and cardiac rehabilitation‏ ‎‡9  1‏
919 ‎‡a  urinarybtypenatriureticpeptidelevelsinthediagnosisandprognosisofheartfailure‏ ‎‡A  Urinary B-type natriuretic peptide levels in the diagnosis and prognosis of heart failure‏ ‎‡9  1‏
919 ‎‡a  usefulnessofacomprehensivecardiovascularmagneticresonanceimagingassessmentforpredictingrecoveryofleftventricularwallmotioninthesettingofmyocardialstunning‏ ‎‡A  Usefulness of a comprehensive cardiovascular magnetic resonance imaging assessment for predicting recovery of left ventricular wall motion in the setting of myocardial stunning.‏ ‎‡9  1‏
919 ‎‡a  usefulnessofconcomitantmyoglobinandtroponinelevationasabiochemicalmarkerofmortalityinnonstsegmentelevationacutecoronarysyndromes‏ ‎‡A  Usefulness of concomitant myoglobin and troponin elevation as a biochemical marker of mortality in non-ST-segment elevation acute coronary syndromes‏ ‎‡9  1‏
919 ‎‡a  usefulnessofntprobnplevelfordiagnosingleftventricularhypertrophyinhypertensivepatientsacardiacmagneticresonancestudy‏ ‎‡A  Usefulness of NT-proBNP level for diagnosing left ventricular hypertrophy in hypertensive patients. A cardiac magnetic resonance study.‏ ‎‡9  1‏
919 ‎‡a  validationofthesamett2r2scoreinanationwidepopulationofnonvalvularatrialfibrillationpatientsonvitaminkantagonists‏ ‎‡A  Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists‏ ‎‡9  1‏
919 ‎‡a  valsalvasinuspseudoaneurysmcausesacutemyocardialinfarctionandstrokesimultaneously‏ ‎‡A  Valsalva sinus pseudoaneurysm causes acute myocardial infarction and stroke simultaneously‏ ‎‡9  1‏
919 ‎‡a  variabilityofntprobnpanditsrelationshipwithinflammatorystatusinpatientswithstableessentialhypertensiona2yearfollowupstudy‏ ‎‡A  Variability of NT-proBNP and its relationship with inflammatory status in patients with stable essential hypertension: a 2-year follow-up study.‏ ‎‡9  1‏
919 ‎‡a  ventricularhypertrophyincreasesntprobnpinsubjectswithandwithouthypertension‏ ‎‡A  Ventricular hypertrophy increases NT-proBNP in subjects with and without hypertension‏ ‎‡9  1‏
919 ‎‡a  whatmeasureofcarotidwallthickeningisthebestatheroscleroticloadingscoreinthehypertensivepatientmaximumormeanvalue‏ ‎‡A  [What measure of carotid wall thickening is the best atherosclerotic loading score in the hypertensive patient: maximum or mean value?]‏ ‎‡9  1‏
919 ‎‡a  relationofrenaldysfunctiontoqualityofanticoagulationcontrolinpatientswithatrialfibrillationthefantasiiaregistry‏ ‎‡A  Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIIA Registry.‏ ‎‡9  1‏
919 ‎‡a  qualityofvitaminkantagonistanticoagulationinspainprevalenceofpoorcontrolandassociatedfactors‏ ‎‡A  Quality of Vitamin K Antagonist Anticoagulation in Spain: Prevalence of Poor Control and Associated Factors.‏ ‎‡9  1‏
919 ‎‡a  relationshipbetweenmyocardialmodellinganddiastolicfunctioninpatientswithessentialhypertension‏ ‎‡A  [Relationship between myocardial modelling and diastolic function in patients with essential hypertension]‏ ‎‡9  1‏
919 ‎‡a  relationshipofadverseeventstoqualityofanticoagulationcontrolinatrialfibrillationpatientswithdiabetesrealworlddatafromthefantasiiaregistry‏ ‎‡A  Relationship of adverse events to quality of anticoagulation control in atrial fibrillation patients with diabetes: Real-world data from the FANTASIIA registry‏ ‎‡9  1‏
943 ‎‡a  200x‏ ‎‡A  2006‏ ‎‡9  2‏
943 ‎‡a  201x‏ ‎‡A  2014‏ ‎‡9  2‏
946 ‎‡a  b‏ ‎‡9  1‏
996 ‎‡2  BNE|XX1717839‏
996 ‎‡2  BNC|981058521701906706‏
996 ‎‡2  ISNI|0000000093963834‏
996 ‎‡2  BNE|XX1084126‏
996 ‎‡2  BNF|16765538‏
996 ‎‡2  ISNI|0000000008820282‏
996 ‎‡2  LC|n 96004681‏
996 ‎‡2  BNE|XX1682439‏
996 ‎‡2  ISNI|0000000459589534‏
996 ‎‡2  NUKAT|n 97081661‏
996 ‎‡2  LC|n 2004095645‏
996 ‎‡2  ARBABN|000070441‏
996 ‎‡2  BNC|981058526535606706‏
996 ‎‡2  NYNYRILM|15273‏
996 ‎‡2  BNE|XX1006304‏
996 ‎‡2  SUDOC|182347656‏
996 ‎‡2  RERO|A012651520‏
996 ‎‡2  LC|no2003120567‏
996 ‎‡2  BNE|XX932940‏
996 ‎‡2  BNE|XX5439064‏
996 ‎‡2  BNE|XX1056787‏
996 ‎‡2  BNE|XX1386587‏
996 ‎‡2  ISNI|0000000439788165‏
996 ‎‡2  BNE|XX1024383‏
996 ‎‡2  BAV|495_328111‏
996 ‎‡2  SUDOC|249891522‏
996 ‎‡2  BNE|XX1469815‏
996 ‎‡2  CAOONL|ncf11384725‏
996 ‎‡2  DNB|1276284713‏
996 ‎‡2  BNCHL|10000000000000000161250‏
996 ‎‡2  ISNI|0000000439657640‏
996 ‎‡2  BNE|XX954567‏
996 ‎‡2  DNB|1321337108‏
996 ‎‡2  BNC|981058507653206706‏
996 ‎‡2  NUKAT|n 2016167307‏
996 ‎‡2  LC|n 85278056‏
996 ‎‡2  LC|no2009159675‏
996 ‎‡2  BNE|XX5179361‏
996 ‎‡2  BNCHL|10000000000000000214956‏
996 ‎‡2  NUKAT|n 2006070321‏
996 ‎‡2  BNC|981058616531806706‏
996 ‎‡2  ISNI|0000000060380237‏
996 ‎‡2  RERO|A026047191‏
996 ‎‡2  J9U|987007441311005171‏
996 ‎‡2  LC|nr2006023017‏
996 ‎‡2  BNF|15920526‏
996 ‎‡2  ISNI|0000000042011243‏
996 ‎‡2  ARBABN|000032441‏
996 ‎‡2  BNE|XX1780343‏
996 ‎‡2  BNE|XX1020927‏
996 ‎‡2  BNE|XX4825238‏
996 ‎‡2  BNE|XX5615117‏
996 ‎‡2  SUDOC|135899834‏
996 ‎‡2  LC|n 2020004066‏
996 ‎‡2  BNC|981060921748106706‏
996 ‎‡2  LC|n 91015093‏
996 ‎‡2  BNE|XX1771941‏
996 ‎‡2  BNE|XX5051435‏
996 ‎‡2  SUDOC|172321441‏
996 ‎‡2  BNC|981058524012706706‏
996 ‎‡2  DNB|140266488‏
996 ‎‡2  PTBNP|171596‏
996 ‎‡2  BNE|XX4897039‏
996 ‎‡2  BNE|XX898454‏
996 ‎‡2  BNF|16703119‏
996 ‎‡2  SUDOC|148445462‏
996 ‎‡2  BNE|XX856761‏
996 ‎‡2  BNE|XX4987665‏
996 ‎‡2  DNB|1056601426‏
996 ‎‡2  BNC|981058523395606706‏
996 ‎‡2  BNE|XX1035725‏
996 ‎‡2  BNF|17770625‏
996 ‎‡2  ISNI|0000000041231949‏
996 ‎‡2  BNC|981058526977006706‏
996 ‎‡2  BAV|495_101622‏
996 ‎‡2  SUDOC|137610289‏
996 ‎‡2  BNCHL|10000000000000000124937‏
996 ‎‡2  ISNI|0000000059559299‏
996 ‎‡2  NII|DA10507213‏
996 ‎‡2  ISNI|000000006811788X‏
996 ‎‡2  BNC|981058515394106706‏
996 ‎‡2  SUDOC|059087765‏
996 ‎‡2  BNF|16510294‏
996 ‎‡2  BNE|XX1556885‏
996 ‎‡2  BNE|XX1055793‏
996 ‎‡2  DNB|133170551‏
996 ‎‡2  LC|no 00039455‏
996 ‎‡2  SUDOC|133508897‏
996 ‎‡2  ISNI|0000000062105992‏
996 ‎‡2  BNC|981058518468706706‏
996 ‎‡2  BNE|XX1149563‏
996 ‎‡2  BNE|XX6435110‏
996 ‎‡2  BNE|XX926351‏
996 ‎‡2  ISNI|0000000066326434‏
996 ‎‡2  BNC|981058608425706706‏
996 ‎‡2  SUDOC|143471007‏
996 ‎‡2  BNE|XX5069295‏
996 ‎‡2  ISNI|0000000060104494‏
996 ‎‡2  ISNI|0000000060725135‏
996 ‎‡2  BNC|981058519878506706‏
996 ‎‡2  ISNI|0000000060716458‏
996 ‎‡2  BNF|14204043‏
996 ‎‡2  BNC|981061132414706706‏
996 ‎‡2  BNE|XX1201111‏
996 ‎‡2  BNE|XX1046669‏
996 ‎‡2  SUDOC|196431913‏
996 ‎‡2  ISNI|0000000036556466‏
996 ‎‡2  BNE|XX893609‏
996 ‎‡2  ISNI|0000000070317346‏
996 ‎‡2  SUDOC|243411626‏
996 ‎‡2  LC|n 2017044231‏
996 ‎‡2  ISNI|0000000060282979‏
996 ‎‡2  LC|n 2013201757‏
996 ‎‡2  BNE|XX5244662‏
996 ‎‡2  BNE|XX5413746‏
996 ‎‡2  BNE|XX1233285‏
996 ‎‡2  ISNI|0000000455446691‏
996 ‎‡2  ISNI|000000005929725X‏
996 ‎‡2  BNE|XX1023747‏
996 ‎‡2  LC|no2011035848‏
996 ‎‡2  BNC|981058530010006706‏
996 ‎‡2  BNE|XX1056297‏
996 ‎‡2  ISNI|0000000420139042‏
996 ‎‡2  BNE|XX5632361‏
996 ‎‡2  ISNI|0000000118550009‏
996 ‎‡2  BNE|XX4981421‏
996 ‎‡2  BNE|XX1719538‏
996 ‎‡2  ISNI|0000000061113480‏
996 ‎‡2  JPG|500040339‏
996 ‎‡2  DNB|1060692287‏
996 ‎‡2  BNC|981058515214306706‏
996 ‎‡2  BNCHL|10000000000000000161273‏
996 ‎‡2  BNC|981058525357406706‏
996 ‎‡2  LC|n 84093996‏
996 ‎‡2  BNE|XX1550247‏
996 ‎‡2  DNB|1158267673‏
996 ‎‡2  JPG|500261573‏
996 ‎‡2  BNE|XX1078641‏
996 ‎‡2  BNE|XX1476092‏
996 ‎‡2  LC|n 2010064308‏
996 ‎‡2  BNC|981058515729306706‏
996 ‎‡2  DNB|1057361801‏
996 ‎‡2  ISNI|000000006073623X‏
996 ‎‡2  BNE|XX1176806‏
996 ‎‡2  BNE|XX1317706‏
996 ‎‡2  DNB|1112561420‏
996 ‎‡2  LC|n 2009012872‏
996 ‎‡2  BNC|981058607982106706‏
996 ‎‡2  LC|nr2006018326‏
996 ‎‡2  DNB|1053063245‏
996 ‎‡2  BNE|XX1728214‏
996 ‎‡2  BNC|981058525721706706‏
996 ‎‡2  BNE|XX1199101‏
996 ‎‡2  BNF|12450015‏
996 ‎‡2  BNE|XX5237606‏
996 ‎‡2  BNE|XX4821147‏
996 ‎‡2  BNE|XX877580‏
996 ‎‡2  LC|no2016025211‏
996 ‎‡2  BNE|XX1610585‏
996 ‎‡2  ISNI|0000000079826235‏
996 ‎‡2  DNB|1057607630‏
996 ‎‡2  BNE|XX1126673‏
996 ‎‡2  BNE|XX1089337‏
996 ‎‡2  PTBNP|963579‏
996 ‎‡2  BNE|XX1050438‏
996 ‎‡2  LC|no2020148261‏
996 ‎‡2  BNE|XX1181378‏
996 ‎‡2  BNE|XX1029323‏
996 ‎‡2  BNC|981058517533806706‏
996 ‎‡2  ISNI|0000000116826083‏
996 ‎‡2  J9U|987007439591705171‏
996 ‎‡2  BNE|XX1138787‏
996 ‎‡2  BNE|XX830942‏
996 ‎‡2  BNE|XX1091569‏
996 ‎‡2  LC|n 88200436‏
996 ‎‡2  BNC|981058513777806706‏
996 ‎‡2  SUDOC|075894742‏
996 ‎‡2  ISNI|0000000116153827‏
996 ‎‡2  BNE|XX1094988‏
996 ‎‡2  RERO|A012074302‏
996 ‎‡2  SUDOC|244971013‏
996 ‎‡2  PLWABN|9810588624905606‏
996 ‎‡2  ICCU|CUBV071351‏
996 ‎‡2  BNE|XX915612‏
996 ‎‡2  LC|no 98113711‏
996 ‎‡2  BNC|981058608267806706‏
996 ‎‡2  ISNI|0000000050306199‏
996 ‎‡2  DNB|105656296X‏
996 ‎‡2  BNE|XX940609‏
996 ‎‡2  LC|n 79087056‏
996 ‎‡2  ISNI|0000000078251564‏
996 ‎‡2  BNF|17131203‏
996 ‎‡2  SUDOC|026652633‏
996 ‎‡2  BNE|XX5163737‏
996 ‎‡2  DNB|1231727314‏
996 ‎‡2  ISNI|0000000059477242‏
996 ‎‡2  BNC|981058523396106706‏
996 ‎‡2  BNE|XX6147509‏
996 ‎‡2  SUDOC|158699866‏
996 ‎‡2  BNE|XX1520614‏
996 ‎‡2  BNE|XX903946‏
996 ‎‡2  BNF|15020599‏
996 ‎‡2  BNE|XX1614039‏
996 ‎‡2  J9U|987007405441405171‏
996 ‎‡2  BNE|XX1722968‏
996 ‎‡2  BNE|XX829980‏
996 ‎‡2  J9U|987007337839805171‏
996 ‎‡2  BNC|981058520642206706‏
996 ‎‡2  BNE|XX1004871‏
996 ‎‡2  SUDOC|069920788‏
996 ‎‡2  ISNI|000000006014789X‏
996 ‎‡2  BNE|XX930252‏
996 ‎‡2  RERO|A003567493‏
996 ‎‡2  ISNI|0000000381557013‏
996 ‎‡2  BNE|XX6190192‏
996 ‎‡2  NKC|xx0316548‏
996 ‎‡2  ISNI|0000000121861916‏
996 ‎‡2  BNE|XX1066522‏
996 ‎‡2  BNE|XX1025521‏
996 ‎‡2  BNE|XX1338167‏
996 ‎‡2  BNE|XX1505779‏
996 ‎‡2  BNCHL|10000000000000000161079‏
996 ‎‡2  BNE|XX5661179‏
996 ‎‡2  BNE|XX1240694‏
996 ‎‡2  ISNI|0000000107722098‏
996 ‎‡2  DNB|143541307‏
996 ‎‡2  BNE|XX1320041‏
996 ‎‡2  LC|n 2015055787‏
996 ‎‡2  SUDOC|113372388‏
996 ‎‡2  ISNI|0000000118192854‏
996 ‎‡2  BNE|XX1429441‏
996 ‎‡2  RERO|A003124298‏
996 ‎‡2  BNE|XX1203468‏
996 ‎‡2  BNE|XX1112763‏
996 ‎‡2  SUDOC|144423715‏
996 ‎‡2  ISNI|0000000059206389‏
996 ‎‡2  SUDOC|168895307‏
996 ‎‡2  ISNI|0000000117077790‏
996 ‎‡2  ISNI|0000000114714029‏
996 ‎‡2  BNC|981058611898606706‏
996 ‎‡2  DNB|1034236172‏
996 ‎‡2  BNC|981058527608306706‏
996 ‎‡2  LC|no2010188101‏
996 ‎‡2  SZ|1112561420‏
996 ‎‡2  BNC|981058509386606706‏
996 ‎‡2  BNF|15055360‏
996 ‎‡2  BIBSYS|90634083‏
996 ‎‡2  LC|no2022134330‏
996 ‎‡2  LC|n 92069911‏
996 ‎‡2  BNE|XX1080133‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏